QIAGEN acquires additional PCR licenses from Roche and Idaho Technology
The agreements cover thermal cycler rights and real-time polymerase chain reaction (PCR) methods for diagnostics and all other applications. In addition, the agreements also cover rights for "high resolution melting curve analysis" (HRM) technology. This novel PCR technology, which is well leveraged by QIAGEN's detection platform Rotor-Gene(TM) Q, opens up a broad array of applications such as mutation discovery, pathogen detection and methylation analysis, as it adds a further information dimension into traditional real time PCR.
With these agreements QIAGEN becomes the first Idaho Technology/ Roche licensee to have full freedom to offer HRM related instruments and reagents under license in all formats and for all purposes in research and diagnostics worldwide. The agreements complement previous settlement arrangements following QIAGEN's 2008 acquisition of Australian PCR cycler manufacturer Corbett.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.